Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2002

View Archived Issues

Methylphenidate improves cognitive symptoms associated with fibromyalgia

Improved sleep physiology, musculoskeletal pain and fatigue on cyclobenzaprine in fibromyalgia

Exelixis and GSK to form alliance in vascular biology, inflammatory disease and oncology

Prostanoid IP antagonists and their use in bladder disorders reported by Roche

Epimmune licenses Valentis technology for use in DNA cancer vaccine products

Progenics receives funding for development of prostate cancer immunotherapies

MDX-010 program expands with phase II trials in metastatic melanoma and prostate cancer

Incara divests liver cell program

Paxil CR improves social functioning in women with PMDD

Arpida presents novel inhibitors of bacterial phosphotransferase system

Novel factor Xa and/or factor VIIa inhibitors in early development at Merck KGaA

AstraZeneca scientists design novel CCR5 modulators

New PDE3B inhibitors prepared and tested at Icos

Abbott reports 5-HT1A receptor ligands and their use in ischemic stroke

New ER-modulatory isoflavonoids for cancer and other conditions

Series of glucocorticoid antagonists under study at Abbott

Memory-enhancing effects demonstrated for MEM-1414 in rat model

Potential of GPI-1046 for maintaining erectile function after radical prostatectomy

Inhibition of caspase 3 attenuates striatal injury induced by malonate

Neuroprotective effects of PRE-703 in rat model of transient focal ischemia

DY-9760e provides neuroprotection in gerbil model of transient forebrain ischemia

Atrix licenses leuprolide acetate products to EmerGen for endometriosis

Topamax sNDA submitted for monotherapy treatment of epilepsy

Peregrine meets with FDA to discuss phase III Cotara trial design

Renzapride reduces GI transit time, increases colonic motility in IBS patients and healthy subjects

NS-2330 enters phase IIb in Alzheimer's disease

Viramidine to enter phase II trials in hepatitis C

Coviracil NDA accepted for filing by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...